HRAS and melanoma: Intriguingly, the same mutual exclusion of papillomavirus positivity and Hras mutations could be observed in SCCs from melanoma patients after treatment with BRAF inhibitors, such as Vemurafenib [127], indicating that cutaneous HPVs (similar to MnPV) may substitute or circumvent activating Hras mutations [128].